ResMAP – a saturation mutagenesis platform enabling parallel profiling of target-specific resistance conferring mutations in Plasmodium

Search results

• Finished

  A Platform for Drug Target Deconvolution and Exploitation

  Gilbert, I. (Investigator), Horn, D. (Investigator), Pawlowic, M. C. (Investigator), Wyatt, P. (Investigator) & Wyllie, S. (Investigator)

  31/12/20 → 30/05/25

  Project: Research

  • Chagas Disease 100%
  • Visceral Leishmaniasis 72%
  • Drug Discovery 67%
  • Molecular Targets 67%
  • Leishmania Donovani 67%

• Structure-Guided Drug Discovery for Malaria and Tuberculosis (joint with Structural Genomics Consortium)

  Gilbert, I. (Investigator), Gray, D. (Investigator), Read, K. (Investigator) & Wyatt, P. (Investigator)

  Bill and Melinda Gates Foundation

  1/01/19 → 6/07/24

  Project: Research

  • Transfer RNA 100%
  • Plasmodium Falciparum 80%
  • Pullout 60%
  • Lysine Transfer RNA Ligase 60%
  • LysR Family 53%

• Wellcome Centre for Anti-Infectives Research

  Baragana, B. (Investigator), Cook, S. (Investigator), De Rycker, M. (Investigator), Fairlamb, A. (Investigator), Ferguson, M. (Investigator), Field, M. (Investigator), Gilbert, I. (Investigator), Gray, D. (Investigator), Horn, D. (Investigator), Lee, M. (Investigator), Pawlowic, M. C. (Investigator), Read, K. (Investigator), Wyatt, P. (Investigator) & Wyllie, S. (Investigator)

  1/04/17 → 1/04/25

  Project: Research

  • Drug Discovery 100%
  • Trypanosoma Cruzi (T. cruzi) 90%
  • Chagas Disease 71%
  • Trypanosoma Cruzi 69%
  • Visceral Leishmaniasis 64%